StemEdit hiPSC B2M/CIITA DKO RPC-LLF-34-F3

Ready-to-use Research-Grade HLA Class I and II double knockout iPSCs made using REPROCELL’s RNA Reprogramming Technology.
These cells feature all the advantages of our RNA reprogramming technology, including no retention of reprogramming factors and easy culture in NutriStem hPSC XF Medium (Cat. No. 01-0005). They have been engineered using OpenCRISPR-1 to contain B2M (HLA Class I) and  CIITA (HLA Class II)  double knockout mutation, which is carefully characterized and offers significant time savings compared to creating your own reprogrammed and edited cell lines.

NOTE:  

These iPSC cell lines are developed and supplied for Research Use Only (RUO). They are not intended for clinical or therapeutic applications. However, this clone has a clinical-grade counterpart available that is suitable for clinical gene editing and downstream clinical development. If you require material for translational or clinical programs, please see Clinical Stem Cell Services or Contact Us for more information.

See also our complete collection of Research Use Only StemRNA™ Induced Pluripotent Stem Cells (iPSCs).

 

Cat. No.:	RCRP052
Mutation:	B2M/CIITA double knockout
Mutation validation:	DNA Sequencing, B2M expression (flow)
Parent Strain ID:	StemRNA Clinical iPSC Clone LLF-34-F3
Donor Blood Type:	O positive
Donor Race:	Caucasian
Donor Sex:	Female
Donor Age:	22
Reprogramming Technology:	StemRNA Clinical Reprogramming Technology
Tissue Source:	Skin (Fibroblasts)
Karyotype:	Normal (46 XX)
Microbiology:	Negative for bacteria, virus, and mycoplasma

 

---

Figure: Immunofluorescence staining (Figure) and flow cytometry analysis (Table) for Pluripotency Markers 

 

---

 

Figure: Expression of B2M in Double Knockout and unedited Wild Type iPSCs 

---

The Role of B2M and CIITA

In humans, the B2M protein is required for the presentation of HLA proteins A-G on the cell surface. Disruption of the B2M gene reduces T-cell activation and interferes with the T-cell-mediated immune response through inhibition of Class I HLA signaling. CIITA regulates the expression of the HLA Class II complex. Knocking out CIITA leads to reduced activity of HLA Class II and suppression of the immune response.

Explore our other StemEdit Research iPSCs. 

---

Stemgent and the StemEdit brand name are trademarks of REPROCELL Inc., Japan.

Product Name: StemEdit hiPSC B2M/CIITA DKO RPC-LLF-34-F3

Product Description: Human iPSCs established from fibroblasts, reprogrammed with REPROCELL's Clinical StemRNA Reprogramming technology, with double knockout in the B2M (HLA Class I) and CIITA (HLA Class II) genes.

Parental Strain ID: StemRNA Clinical iPSC Clone LLF-34-F3

Tissue Source: Skin (fibroblasts)

Catalog Number: RCRP052

Donor Information

• Race: Caucasian
• Sex: Female
• Age: 22 years old

Precryopreservation Culture Conditions

• Culture Medium: NutriStem hPSC XF Culture Medium (Cat No 01-0005)
• Culture Matrix: iMatrix-511 (Cat. No. NP892-011)
• Cryopreservation Medium: NutriFreez™ D10 Freezing Medium (Cat. No. 01-0020-50)

Size: 1 vial, 1 × 10⁶ cells per vial

Storage: Store in liquid nitrogen vapor phase.

Quality Control

• Pluripotency by ICC, flow cytometry: Pass
• Knockout verification by NGS, flow cytometry: Pass
• Viability: ≥ 70 %
• Bacteria: Negative
• Mycoplasma: Negative
• Virus (HIV1&2, HBV, HCV): Negative
• Karyotype: 46, XX

Sterility: Sterile

Notice To Purchaser: This product is intended for Research Use Only. Commercial Use may require additional agreements. Please contact info-us@reprocell.com for more information. This Product is not intended for Clinical or Diagnostic Use.

Protocol: Thawing StemRNA hiPSCs